Evidence map›Paper›PMID 39982587›Full record

ArticleClinical and experimental nephrology2025

Efficacy of urinary [TIMP-2]⋅[IGFBP7], L-FABP, and NGAL levels for predicting community-acquired acute kidney injury in Japanese patients: a single-center, prospective cohort study.

Satoshi Inotani, Takeshi Kashio, Yuki Osakabe, Tatsuki Matsumoto, Yoshiki Nagao, Masayuki Ishihara, Hideki Iwata, Keita Mitani, Yutaka Hatakeyama, Taro Horino

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Satoshi InotaniDepartment of Endocrinology, Metabolism and Nephrology, Kochi Medical School, Kochi University, Kohasu, Oko-cho, Nankoku, Kochi, 783-8505, Japan.
Takeshi KashioDepartment of Endocrinology, Metabolism and Nephrology, Kochi Medical School, Kochi University, Kohasu, Oko-cho, Nankoku, Kochi, 783-8505, Japan.
Yuki OsakabeDepartment of Endocrinology, Metabolism and Nephrology, Kochi Medical School, Kochi University, Kohasu, Oko-cho, Nankoku, Kochi, 783-8505, Japan.
Tatsuki MatsumotoDepartment of Endocrinology, Metabolism and Nephrology, Kochi Medical School, Kochi University, Kohasu, Oko-cho, Nankoku, Kochi, 783-8505, Japan.
Yoshiki NagaoDepartment of Paediatrics, Kochi Medical School, Kochi University, Kohasu, Oko-cho, Nankoku, Kochi, 783-8505, Japan.
Masayuki IshiharaDepartment of Paediatrics, Kochi Medical School, Kochi University, Kohasu, Oko-cho, Nankoku, Kochi, 783-8505, Japan.
Hideki IwataDepartment of Anaesthesiology and Intensive Care Medicine, Kochi Medical School, Kochi University, Kohasu, Oko-cho, Nankoku, Kochi, 783-8505, Japan.
Keita MitaniCentre of Medical Information Science, Kochi Medical School, Kochi University, Kohasu, Oko-cho, Nankoku, Kochi, 783-8505, Japan.
Yutaka HatakeyamaCentre of Medical Information Science, Kochi Medical School, Kochi University, Kohasu, Oko-cho, Nankoku, Kochi, 783-8505, Japan.
Taro HorinoDepartment of Endocrinology, Metabolism and Nephrology, Kochi Medical School, Kochi University, Kohasu, Oko-cho, Nankoku, Kochi, 783-8505, Japan. horinott@yahoo.co.jp.ORCID http://orcid.org/0000-0003-0695-7981

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe combination of urinary tissue inhibitor of metalloproteinase 2 (TIMP-2) and insulin-like growth factor-binding protein 7 (IGFBP7) ([TIMP-2]⋅[IGFBP7]) has emerged as a strong predictor of acute kidney injury (AKI), which is associated with poor outcomes. However, most studies have focused on non-Asian populations, and comparisons of [TIMP-2]⋅[IGFBP7] with other AKI biomarkers in Asian populations have not been performed. Furthermore, no study has examined the efficacy of [TIMP-2]⋅[IGFBP7] for predicting community-acquired AKI.

methodsWe prospectively enrolled adult patients at Kochi Medical School Hospital in Kochi, Japan, and performed a receiver-operating characteristic (ROC) curve analysis to assess the ability of [TIMP-2]⋅[IGFBP7], neutrophil gelatinase-associated lipocalin (NGAL), and liver fatty acid-binding protein (L-FABP) measured at the time of admission to predict AKI.

resultsOf the 170 enrolled patients, 40 (23.5%) developed AKI. Risk factors for AKI development were male sex, history of hypertension, low albumin levels, and high [TIMP-2]⋅[IGFBP7] and NGAL levels. The ROC curve analysis showed that the area under the ROC curve (AUC) of [TIMP-2]•[IGFBP7] for predicting AKI was 0.804 (95% confidence interval [CI], 0.728-0.880); however, the AUCs of L-FABP and NGAL were 0.688 (95% CI, 0.594-0.782) and 0.726 (95% CI, 0.639-0.813), respectively.

conclusionUrinary [TIMP-2]⋅[IGFBP7] is a good predictor of community-acquired AKI.

Indexed as

Acute Kidney InjuryFatty Acid-Binding ProteinsInsulin-Like Growth Factor Binding ProteinsLipocalin-2Tissue Inhibitor of Metalloproteinase-2AdultAgedAged, 80 and overBiomarkersEast Asian PeopleFemaleHumansJapanMaleMiddle AgedPredictive Value of TestsBiomarkersFABP1 protein, humanFatty Acid-Binding Proteinsinsulin-like growth factor binding protein-related protein 1Insulin-Like Growth Factor Binding ProteinsLCN2 protein, humanLipocalin-2TIMP2 protein, humanTissue Inhibitor of Metalloproteinase-2Acute kidney injuryBiomarkerInsulin-like growth factor-binding protein 7Liver fatty acid-binding proteinNeutrophil gelatinase-associated lipocalinTissue inhibitor of metalloproteinase 2

Identifiers

PMID39982587
PMCPMC12204939

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.